NasdaqGS:GHHealthcare
A Look At Guardant Health (GH) Valuation After Insider Selling And New Cancer Testing Updates
Guardant Health (GH) has been in focus after disclosures that key insiders and a major shareholder reduced their holdings, along with fresh clinical data on its Guardant Reveal test and a new Shield-based colorectal cancer screening grant program.
See our latest analysis for Guardant Health.
Guardant Health’s recent insider selling and fresh clinical data arrive after a mixed few weeks for the share price. The stock has a 9.71% 90 day share price return and a 117.89% 1 year total shareholder...